Skin and soft tissue infections (SSTIs) carry significant economic burden, as wellas morbidity and mortality, especially when caused by methicillin-resistant Staphylococcusaureus (MRSA). Several new MRSA-active antibiotics have been developed, includingsemisynthetic glycopeptides (telavancin, dalbavancin and oritavancin). Of these, dalbavancinand oritavancin offer extended dosing intervals.

Fonte: Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: a systematic review, network meta-analysis and cost analysis – Clinical Microbiology and Infection